Phase 1 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with liver cancer (hepatocellular carcinoma) that has spread or cannot be surgically removed, confirmed by a biopsy or scan, or by specific liver disease guidelines if you also have cirrhosis.
- A test on your tumor tissue has shown a positive result for a protein called GPC3 (confirmed by the trial's central laboratory).
- Your cancer cannot be treated with, or has continued to grow after, surgery, tumor-destroying treatments, or procedures to block blood supply to the tumor.
- You are generally able to carry out daily activities with little or no limitation (confirm with trial site what this means for your situation).
- You have at least one area of cancer that can be measured by a CT scan or MRI scan, assessed within the last 28 days before starting the trial.
- Your blood tests show that your bone marrow, liver, kidneys, and other organs are functioning well enough (confirm specific requirements with trial site).
Who may not be able to join:
- You have a specific rare subtype of liver cancer, such as fibrolamellar, sarcomatoid, or a mixed liver/bile duct cancer type.
- You have cancer that has spread to the brain or spinal cord, unless you meet certain additional conditions (confirm with trial site).
- You have had a serious episode of brain confusion or mental decline related to liver disease (Grade 2 or higher) in the past 12 months.
- You have a significant build-up of fluid in your abdomen that is causing noticeable problems.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (+)1-888-84 22937
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 1 (dose escalation): Occurrence and severity of TEAEs; Part 1 (dose escalation): Recommended safe and active dose (RSAD); Part 2 (dose expansion): Occurrence and severity of TEAEs; Part 2 (dose expansion): ORR using RECIST 1.1 by investigator assessment; Part 2 (dose expansion): DCR using RECIST 1.1 by investigator assessment; Part 2 (dose expansion): DoR using RECIST 1.1 by investigator assessment; Part 2 (dose expansion): PFS using RECIST 1.1 by investigator assessment; Parts 3 and 4 (dose expansion in combination): Occurrence and severity of TEAEs; Parts 3 and 4 (dose expansion in comb...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.